Financial cycles of acquisitions and ‘buybacks’ threaten public access to breakthrough drugs
28 July 2016An analysis of a new drug’s journey to market, published today in the BMJ, shines a light on financial practices that see some major pharmaceutical companies relying on a cycle of acquisitions, profits from high prices, and shareholder-driven manoeuvres that threatens access to medicines for current and future patients.
